CAI ▼ -12.5% - Caris Life Sciences, Inc.
$CAI reported Q3 2026 EPS of $0.05, beating the $0.02 estimate by 150.0%. Revenue of $275.4M beat the $254.4M estimate by 8.2%.
04-NOV-2026 04:28 PM ET
Share this post
More filings for $CAI
CAI ▼ -13.2% - Caris Life Sciences, Inc.Nov 4, 2026CAI ▲ +0.3% - Caris Life Sciences, Inc.Oct 19, 2026CAI ▼ -2.4% - Caris Life Sciences, Inc.Oct 15, 2026CAI ▲ +0.1% - Caris Life Sciences, Inc.Oct 14, 2026CAI ▼ -1.1% - Caris Life Sciences, Inc.Sep 8, 2026CAI ▲ +1.2% - Caris Life Sciences, Inc.Sep 2, 2026
View full $CAI filing history →💬 Comments
Loading comments…
Leave a comment